首页> 外文期刊>The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology >Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.
【24h】

Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.

机译:食物,抗酸剂和H2拮抗剂雷尼替丁对健康受试者中口服直接Xa抑制剂BAY 59-7939(利伐沙班)吸收的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

To investigate the influence of food and administration of an antacid (aluminum-magnesium hydroxide) or ranitidine on the absorption of BAY 59-7939 (rivaroxaban), 4 randomized studies were performed in healthy male subjects. In 2 food interaction studies, subjects received BAY 59-7939, either as two 5-mg tablets (fasted and fed), four 5-mg tablets (fasted), or one 20-mg tablet (fasted and fed). In 2 drug interaction studies, BAY 59-7939 (six 5-mg tablets) was given alone or with ranitidine (150 mg twice daily, preceded by a 3-day pretreatment phase) or antacid (10 mL). Plasma samples were obtained to assess pharmacokinetic and pharmacodynamic parameters of BAY 59-7939. In the presence of food, time to maximum concentration (t(max)) was delayed by 1.25 hours; maximum concentration (C(max)) and area under the curve (AUC) were increased, with reduced interindividual variability at higher doses of BAY 59-7939. Compared with baseline, BAY 59-7939 resulted in a relative increase in maximum prothrombin time (PT) prolongation of 44% (10 mg) and 53% (20 mg) in the fasted state, compared with 53% and 83% after food. Time to maximum PT prolongation was delayed by 0.5 to 1.5 hours after food, with no relevant influence of food type. No significant difference in C(max) and AUC was observed with coadministration of BAY 59-7939 and ranitidine or antacid.
机译:为了调查食物和服用抗酸剂(氢氧化铝镁)或雷尼替丁对BAY 59-7939(利伐沙班)吸收的影响,在健康男性受试者中进行了4项随机研究。在2项食物相互作用研究中,受试者接受了BAY 59-7939,为2片5毫克片剂(禁食和进食),4片5毫克片剂(禁食)或1片20毫克片剂(禁食和进食)。在2项药物相互作用研究中,单独或与雷尼替丁(每天两次两次,每次150毫克,随后为期3天的预处理阶段)或抗酸药(10毫升)一起服用BAY 59-7939(六片5毫克片剂)。获得血浆样品以评估BAY 59-7939的药代动力学和药效学参数。在有食物的情况下,达到最大浓度(t(max))的时间延迟了1.25小时;最大剂量(C(max))和曲线下面积(AUC)增加,且在更高剂量的BAY 59-7939下个体间变异性降低。与基线相比,BAY 59-7939导致禁食状态下最大凝血酶原时间(PT)延长相对增加了44%(10 mg)和53%(20 mg),而进餐后为53%和83%。食物后最大PT延长时间延迟了0.5到1.5小时,而没有食物类型的相关影响。与BAY 59-7939和雷尼替丁或抗酸药合用,未观察到C(max)和AUC的显着差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号